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The Editorial on the Research Topic
The Emerging Role for PP2A in Hematologic Malignancies
While we strive to understand the role of kinases in signal transduction pathways that mediate leu-
kemogenesis, drug resistance, and homeostasis of leukemia cells, the role of the protein phosphatases 
that are also critical in these cascades is under studied. The PP2A serine/threonine family of protein 
phosphatases contains many tumor suppressors, and these enzymes regulate a large number of 
survival molecules that are essential to leukemia cell survival. In this Research Topic, The Emerging 
Role for PP2A in Hematologic Malignancies, the authors review the current state of knowledge on 
PP2A role in leukemia and discuss the emergence of new therapeutic strategies to target PP2A for 
leukemia therapy.
A background in PP2A structure and function is provided by Haesen et al. in “The basic biology 
of PP2A in hematologic cells and malignancies.” This review introduces us to the subunits that 
comprise the PP2A heterotrimer – the catalytic C subunit and scaffold A subunit that make up the 
catalytic core and the regulatory B subunits that drive isoform specificity and function. The authors 
provide detailed information on the expression of these subunits in hematologic tissues as well as 
the various cellular proteins that regulate PP2A function including the various inhibitors such as 
SET that have been implicated in suppressing PP2A tumor suppressor function in many cancers. 
The review provides an excellent description of the post-translational modifications that control how 
the PP2A heterotrimer assembles.
In “Therapeutic Reactivation of Protein Phosphatase 2A in Acute Myeloid Leukemia,” Ramaswamy 
et  al. cover strategies to re-activate PP2A for leukemia therapy. The authors offer a mechanistic 
insight into how the protein phosphatase overcomes suppression in the leukemia cells. The authors 
also discuss how expression of the various subunits that comprise the PP2A heterotrimer vary in 
AML patients compared to normal individuals, suggesting that there may be distinct sets of PP2A 
isoforms in the leukemia patients.
Oaks and Ogretmen discuss the role sphingolipids such as ceramide play in controlling PP2A 
activity in “Regulation of PP2A by Sphingolipid Metabolism and Signaling.” Ceramides are sphin-
golipids that are key modulators of leukemia cell survival, and the review discusses how ceramides 
regulate PP2A function directly and indirectly via the SET inhibitor. The review also discusses the 
biology of FTY-720, a sphingosine analog that has been proposed for therapy of leukemia.
In “PP2A: The Achilles Heal in Myelodysplastic Syndrome (MDS) with 5q Deletion,” Sallman 
et al. discuss mechanistic aspects of PP2A catalytic C alpha subunit deletion in MDS. The PP2A 
subunit C alpha (PPP2CA) gene is located on human chromosome 5q, and this chromosomal 
region is deleted in 15% of MDS patients. The review discusses lenalidomide therapy for MDS and 
importance of PP2A as a lenalidomide target and the ability of PP2A catalytic C alpha subunit to act 
as a resistance factor to the drug.
Ciccone et al. discuss PP2A as a therapeutic target in leukemia in “From the Biology of PP2A to 
the PP2A-Activating Drugs (PADs) for Therapy of Hematologic Malignancies.” This review discusses 
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the development and current use of PADS that include FTY-720, 
OP449, and AALS (a FTY-720 analog). The review includes 
background on cellular inhibitors such as SET and the mecha-
nistic studies that linked SET to BCR ABL in chronic myeloid 
leukemia and Ph+ acute lymphoblastic leukemia. As discussed 
in the review, many of the PADs being developed target the SET 
inhibitor.
Arriazu et al. continue discussions of PP2A as a therapeutic 
target with emphasis on AML in “Protein Phosphatase 2A as a 
Therapeutic Target in Acute Myeloid Leukemia.” The review 
provides a comprehensive look at the state of current knowledge 
of expression of the various PP2A subunits in AML. The authors 
also provide detailed information on mechanistic aspects of 
the various PP2A isoforms and cellular inhibitors that impact 
leukemia cell survival. The review also provides information on 
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A), a cel-
lular inhibitor of PP2A that is not as well studied as SET.
Finally, Ruvolo discusses how microRNAs (miRs) control 
various PP2A subunits and PP2A regulators and the emerging 
role of PP2A as a regulator of miR expression in “The Interplay 
between PP2A and miRs in Leukemia.” Competition between 
PP2A subunits is an important component in regulating multiple 
PP2A subunits and miRs may play a role in this process. The 
review also discusses the role of the PP2A B55 alpha regulatory 
subunit in controlling MYC and also miRs that are not dependent 
on MYC regulation.
It is our hope that this Research Topic encourages greater 
interest in PP2A role as a potential tumor suppressor in leukemia. 
A better understanding of PP2A contribution in MDS, leukemia, 
and other hematologic malignancies will hopefully encourage 
development of PADs for clinical use for therapy and also inspire 
the creation of newer PADs that will hopefully activate the PP2A 
isoforms that prove to be true tumor suppressors.
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